Supercharged immune cells take on relapsed leukemia in new trial
NCT ID NCT03068819
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new approach for children and adults whose acute myeloid leukemia (AML) came back after a stem cell transplant. Researchers gave patients a special type of immune cell called cytokine-induced memory-like natural killer (CIML NK) cells, along with donor immune cells, to try to fight the leukemia. The goal was to see if this combination was safe and could help patients achieve remission. The trial enrolled 62 participants and looked at both safety and how well the treatment worked.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cytokine-induced memory-like natural killer (CIML NK) cells
- What this could lead to
- If this works, it could offer a more effective treatment for patients whose leukemia returns after a stem cell transplant, potentially improving remission rates and survival.
- What could go wrong
- This is an early-phase trial with a small number of participants, so results may not apply to everyone. There are risks of graft-versus-host disease, infections, and other side effects from the cell infusions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill keep blood cancer at bay after a stem cell transplant?
- Could muscle loss predict blood cancer outcomes?
- Can a modified enzyme starve Hard-to-Treat blood cancers?
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- Talking about the end: could guided conversations reduce futile cancer treatments?